Middle East and Africa Multiomics Market Size, Share & Trends Analysis Report By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics), By Country (Brazil, Mexico, Argentina, Chile, Colombia) and Forecast, 2026-2034

Middle East and Africa Multiomics Market Trends

Single-cell, spatial and multimodal workflows reshape research

Multi-layer biological analysis is shifting from separate assays toward integrated sequencing, single-cell, spatial and computational workflows. Illumina disclosed Perturb-seq configurations supporting 10,000, 100,000 and 1 million cells per sample and collaboration aimed at enabling a 5 billion-cell atlas ecosystem within three years. Its spatial platform provides a capture area reported at 9 times larger and resolution 4 times greater than existing technologies referenced by the company.

Cloud-based integration is simultaneously reducing the informatics barrier. Illumina Connected Multiomics entered commercial availability after feedback from 40 early-access users, integrating genomic, transcriptomic, proteomic and epigenetic analysis. In the Middle East, population-scale sequencing is accelerating the transition from isolated genomic datasets toward longitudinal clinical and multi-layer molecular research, with the UAE dataset already covering hundreds of thousands of genomes.

Middle East and Africa Multiomics Market Drivers

Population genomics and precision medicine infrastructure accelerate adoption

Government-backed genomic medicine is creating a foundation for broader multiomic research. The UAE's reported 802,000 sequenced genomes, including 702,000 Emiratis, represent coverage approaching three-quarters of the Emirati population, while 55 sequencing systems provide substantial laboratory capacity. Such scale supports downstream transcriptomic, proteomic and metabolomic studies for rare diseases, oncology and drug discovery. The increasing integration of genomic information into clinical programs also expands demand for analytics, sequencing consumables and high-throughput infrastructure.

Middle East and Africa Multiomics Market Restraints

High computational complexity and workflow standardization requirements restrict scaling

Multi-layer experiments generate substantially greater computational and storage requirements than individual assays, while single-cell proteomics can involve picogram-level samples and potentially thousands of proteins across thousands of cells. Data normalization, missing values, reproducibility and cross-platform integration remain technical constraints. At population scale, datasets exceeding 800,000 genomes intensify requirements for secure infrastructure, governance and specialized bioinformatics personnel, while multimodal experiments can combine 2, 3 or more molecular layers per sample.

Middle East and Africa Multiomics Market Opportunities

Integrated genomic and epigenomic workflows open precision-medicine opportunities

Integrated assays are reducing the number of separate workflows required to investigate disease biology. Illumina's 5-base approach enables genetic-variant and DNA-methylation detection from a single sample, while its single-cell roadmap scales from 10,000 to 1 million cells per sample and supports experiments ranging from 100 gRNA sequences to more than 10,000 gRNAs. Combined with regional genomic datasets covering hundreds of thousands of individuals, these technologies create opportunities across biomarker discovery, oncology, rare diseases and pharmaceutical research.

Challenges in Middle East and Africa Multiomics Market

Data interoperability and specialist requirements complicate clinical translation

Integrating genomic, transcriptomic, proteomic and metabolomic information requires harmonized pipelines across 4 or more molecular layers, specialized statistical models and reproducible analytical standards. Single-cell studies can simultaneously involve thousands of proteins and thousands of cells, magnifying missing-value and normalization problems. Population-scale programs exceeding 700,000 participants further require stringent privacy controls, secure computing and clinical interpretation frameworks before integrated molecular datasets can be routinely deployed in healthcare.

Middle East and Africa Multiomics Market Segmentation

The market is segmented by omics type, application, technology, offering and end user. Within the quantitative omics dataset, genomics dominates at 33.70% of 2026 revenue, transcriptomics represents 18.85%, and proteomics accounts for 14.17%. Microbiomics records the highest supplied CAGR at 16.41%.

By Omics Type

Genomics is the largest category, increasing from USD 92.89 million in 2025 to USD 107.51 million in 2026 and USD 346.19 million by 2034 at 15.74% CAGR. Its approximately 33.70% 2026 contribution reflects established sequencing infrastructure and population-genomics programs.

Microbiomics is the fastest-growing omics category at 16.41% CAGR, advancing from USD 20.01 million in 2026 to USD 67.48 million in 2034. Transcriptomics reaches USD 200.03 million at 16.21% CAGR, proteomics USD 151.61 million at 16.33%, metabolomics USD 130.66 million at 16.12%, epigenomics USD 96.98 million at 15.84%, and lipidomics USD 52.78 million at 15.49%.

By Application

Drug discovery and development, precision medicine, biomarker identification, clinical diagnostics, agriculture, nutrigenomics, infectious-disease surveillance and systems biology constitute the principal application categories. Population resources involving 702,000 Emirati genomes illustrate the scale available for disease association, biomarker and therapeutic-target studies.

The supplied numerical tables do not allocate USD value or CAGR by application; consequently, application-level revenue or growth percentages are not extrapolated. Quantitative analysis remains anchored to the supplied USD 319.24 million regional 2026 total and USD 1,053.09 million 2034 forecast.

By Technology

Next-generation sequencing is a foundational technology alongside mass spectrometry, microarrays, single-cell analysis, real-time PCR and integration platforms. Current single-cell workflows can process configurations ranging from 10,000 to 1 million cells per sample, demonstrating the increasing throughput available for multimodal research.

The supplied dataset provides no technology-specific USD values or CAGRs; therefore, no unsupported technology split is assigned. Technology adoption is instead assessed against the overall 16.2% regional forecast trajectory.

By Offering

Software and services, instruments and consumables form the offering structure. Cloud-based multimodal platforms increasingly consolidate datasets that previously required multiple analytical tools; Illumina's platform launched after evaluation by 40 early-access users.

No offering-level revenue allocation was supplied. Accordingly, the analysis retains the reported regional totals of USD 275.00 million in 2025, USD 319.24 million in 2026 and USD 1,053.09 million in 2034 without manufacturing an offering split.

By End User

Pharmaceutical and biotechnology companies, academic institutions, CROs, hospitals and clinics, and government/public-health agencies constitute the major end-user groups. The UAE's population program, incorporating more than 800,000 sequenced genomes, demonstrates the scale at which government, healthcare and research organizations can support molecular-data generation.

No end-user-specific market values or CAGRs were supplied. Consequently, quantitative end-user estimates are not fabricated, while the overall regional forecast remains 16.2% CAGR through 2034.

Middle East and Africa Multiomics Market Countries Outlook

The supplied geographic dataset covers the United Arab Emirates, Saudi Arabia, South Africa, Egypt, Nigeria and Turkey. The requested Brazil, Mexico, Argentina, Chile and Colombia breakdown is not used because those countries are outside the stated Middle East and Africa scope and no mandatory numerical data were supplied for them.

United Arab Emirates

The UAE contributes approximately 51.62% of 2026 country-level value, rising from USD 141.76 million in 2025 to USD 164.80 million in 2026 and USD 549.66 million by 2034, at 16.25% CAGR. Population-scale sequencing of 802,000 genomes strengthens the country's position in precision medicine and biomarker research.

Saudi Arabia

Saudi Arabia accounts for approximately 18.16% of 2026 value at USD 57.97 million. Revenue is projected to reach USD 186.14 million by 2034, representing 15.70% CAGR and an increase of USD 128.17 million from 2026.

South Africa

South Africa represents approximately 9.17% of 2026 value, increasing from USD 25.22 million in 2025 to USD 29.28 million in 2026 and USD 96.73 million in 2034, at 16.11% CAGR.

Egypt, Nigeria and Turkey

Egypt reaches USD 26.46 million in 2026 and USD 87.95 million in 2034 at 16.20% CAGR. Nigeria increases from USD 16.12 million to USD 53.19 million at 16.09% CAGR, while Turkey expands from USD 24.61 million to USD 79.42 million at 15.77% CAGR.

Top players in Middle East and Africa Multiomics Market

1. Illumina
2. Thermo Fisher Scientific
3. QIAGEN
4. Agilent Technologies
5. Bruker
6. Bio-Rad Laboratories
7. 10x Genomics
8. Standard BioTools
9. BGI Genomics
10. Pacific Biosciences
11. Oxford Nanopore Technologies
12. Waters Corporation
13. SCIEX
14. M42

Top two companies

• Illumina

Illumina maintains strong positioning through sequencing, single-cell, spatial, epigenomic and multimodal informatics capabilities. Its Perturb-seq configurations span 10,000, 100,000 and 1 million cells per sample, while its spatial platform reports a 9× larger capture area and 4× greater resolution versus referenced alternatives. Connected Multiomics adds cloud-based integration across multiple molecular layers. A defensible company-specific regional revenue percentage is not publicly disclosed; assigning a fabricated percentage would conflict with the mandatory-data requirement.

• Thermo Fisher Scientific

Thermo Fisher participates across sequencing workflows, mass spectrometry, PCR, laboratory instruments, consumables and analytical software, providing exposure to multiple stages of multiomic research. Its broad technology footprint positions the company across genomics, proteomics and metabolomics workflows rather than a single molecular layer. No verified Middle East and Africa multiomics-specific percentage revenue share is available in the supplied data; therefore, no unsupported company-share figure is assigned.

Recent Developments in Middle East and Africa Multiomics Market

• 2026: Illumina announced Connected Multiomics, following input from 40 early-access users, integrating multiple biological data modalities into a cloud-based analytical environment.
• 2026: Abu Dhabi's Department of Health continued supporting the Emirati Reference Genome platform for population-specific variant interpretation and precision medicine.
• 2025: Illumina introduced its 5-base solution combining genomic-variant and methylation detection in a single workflow.
• 2025: Illumina outlined Perturb-seq formats covering 10,000, 100,000 and 1 million cells per sample, alongside spatial and multimodal technologies.
• 2025: M42 was reported to have sequenced 802,000 genomes, including 702,000 Emiratis, supported by 55 sequencing devices, creating a major regional population-genomics resource.

Research Methodology

The assessment uses the supplied mandatory quantitative tables as the primary basis for all market values, country contributions, omics-type contributions, CAGRs and 2026–2034 forecasts. Percentage shares are calculated directly from supplied totals—for example, UAE 2026 revenue of USD 164.80 million divided by the USD 319.24 million country total produces approximately 51.62%, while genomics revenue of USD 107.51 million divided by the USD 318.99 million omics total produces approximately 33.70%. Secondary evidence is restricted to technology, infrastructure and company developments from cited public sources. No unsupported regional, application, technology, offering, end-user or company-share values have been fabricated.